Aridis Pharma gets EMA orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF).

AR-501 is an inhaled formulation of gallium citrate, a non-antibiotic, anti-infective agent being developed as a self-administered, weekly treatment. AR-501 demonstrated efficacy against antibiotic-resistant strains, and a low resistance profile in preclinical studies.

The candidate received FDA orphan drug designation for the same indication last month.

“Receiving orphan designation from the EMA for AR-501 is an important step in ensuring the program is well positioned from a global regulatory development pathway standpoint as we continue to advance its ongoing Phase 1/2a clinical trial,” Vu Truong, Aridis’ CEO, said in a statement.

Aridis expects to report data from the Phase 1 portion, which consists of healthy subjects, in the first quarter of 2020; and the Phase 2a portion, in CF patients, in the second quarter of 2021.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.